Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Irish Drug Prices Face Annual Cuts Under New Four-Year Deal

Executive Summary

The new Irish drug pricing deal, aimed at achieving savings of €785m over four years, provides for regular price cuts and rebates, price reductions for biologicals when biosimilar versions are marketed, and a new mechanism for dealing with high-cost medicines.

You may also be interested in...



Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures

The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.

Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures

The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.

Ireland Prepares New Biosimilar Policy To Improve Access, Boost Industry

Ireland is developing a new policy intended to increase the use of biosimilars, taking account of initiatives in other countries. The government says the aim is to help boost competition and access to cheaper biologicals.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC097179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel